A chondrosarcoma is a type of cancer that starts in the cartilage cells. It's usually slow-growing but can become aggressive. It most often occurs in the pelvis or near the ends of long bones, typically in older adults.
Every report comes from a Lived member, sent anonymously.
Have you tried Radiation Therapy for Chondrosarcoma?
Chondrosarcoma is a rare cancer made of cells that produce cartilage, the tough, flexible tissue that cushions the ends of bones and shapes structures such as the nose and ears. It usually starts inside a bone or on its surface, most often in the thigh bone, pelvis, upper arm or shoulder. It is the second most common cancer that begins in bone itself (rather than spreading there from somewhere else), and it is mainly a disease of adults, usually diagnosed after age 40. Most chondrosarcomas grow slowly, so symptoms often build over many months. The usual first sign is a deep, aching pain in a bone or joint that gradually worsens and is often worse at night. Some people notice a hard lump or swelling instead, and a bone weakened by the tumor can occasionally break with little or no injury. Chondrosarcoma is a family of tumors rather than a single disease. Conventional chondrosarcoma makes up about 85% of cases and is usually slow growing. The rarer subtypes behave very differently: dedifferentiated chondrosarcoma is aggressive and tends to spread early, mesenchymal chondrosarcoma mostly affects teenagers and young adults, and clear cell chondrosarcoma is usually low grade. The subtype and grade shape almost every decision about treatment.
Most chondrosarcomas develop without any identifiable cause, and there is no known lifestyle factor that brings one on. Some start in a benign (noncancerous) cartilage tumor. An osteochondroma is a bony outgrowth with a cartilage cap on the surface of a bone; an enchondroma is a lump of cartilage inside a bone. Either can occasionally turn into chondrosarcoma. The risk is higher in people who have many of these growths, but how much higher depends on the condition. In hereditary multiple osteochondromas, an inherited condition with many osteochondromas, the lifetime risk is modest, and most people never develop cancer. In Ollier disease and Maffucci syndrome, conditions with multiple enchondromas, the risk is substantial: in one large study about 4 in 10 people developed chondrosarcoma, more often when enchondromas were in the long bones or the pelvis. Regular follow-up with a specialist is usual for these conditions, and a growth that changes deserves attention. Many chondrosarcomas carry changes in IDH1 or IDH2, genes for enzymes (isocitrate dehydrogenase) involved in cell energy use. These changes arise in the tumor itself. Testing for them can help a pathologist confirm the diagnosis and can determine whether someone qualifies for certain clinical trials.
Diagnosis usually begins with an x-ray of the painful area. Chondrosarcoma often has a recognizable look, with flecks of calcium scattered through the tumor in a pattern radiologists describe as rings and arcs. MRI (magnetic resonance imaging) and CT (computed tomography) scans then show how far the tumor reaches inside the bone and into nearby tissue, and scans of the chest or whole body check whether it has spread. Imaging alone cannot settle the question, because a low-grade chondrosarcoma and a benign enchondroma can look very similar. A biopsy, in which a sample of the tumor is removed (often with a needle) and examined by a pathologist, is needed to confirm the diagnosis, the subtype and the grade. The sample is taken from the most aggressive-looking part of the tumor. Grade describes how abnormal the cells look under the microscope, from grade 1 (slow growing and unlikely to spread) to grade 3 (faster growing and more likely to spread). Grade can be hard to pin down from a small sample, which is one reason surgeons often plan a wide removal rather than relying on the biopsy alone.
Surgery is the main treatment and the one most likely to cure the cancer. The aim is to remove the entire tumor with a rim of healthy tissue around it, called a clear margin, because tumor left at the edges greatly raises the chance that it returns or spreads. For some low-grade tumors in an arm or leg, a surgeon may instead scrape the tumor out of the bone (curettage) and treat the cavity with freezing, bone cement or chemicals to destroy any remaining cells. Higher-grade tumors usually need wider removal of the affected bone, which is then rebuilt with a metal implant, a bone graft or both. Most people keep the limb; amputation is a last resort for tumors that cannot otherwise be removed safely. Tumors in the pelvis, spine or base of the skull are harder to remove and call for highly specialized surgery. Most chondrosarcomas respond poorly to chemotherapy and standard radiation, partly because the cells divide slowly and sit within dense cartilage that has little blood supply. Radiation is used when a tumor cannot be fully removed or when surgery would cause unacceptable harm. Proton therapy, a form of radiation that can deliver a high dose with less damage to surrounding tissue, has shown better tumor control than conventional radiation for tumors at the base of the skull. Chemotherapy has a clearer role in the rarer fast-growing subtypes. For mesenchymal chondrosarcoma that has not spread, surgery combined with chemotherapy is the standard approach, and chemotherapy may also be offered for dedifferentiated chondrosarcoma. For advanced conventional chondrosarcoma, newer targeted medicines are being tested in clinical trials and are not yet standard treatment, including drugs aimed at the IDH1 gene change and an antibody designed to trigger cancer cell death, so asking about clinical trials is worthwhile. Because the cancer is rare, treatment is best planned with a team that specializes in sarcoma.
The outlook for chondrosarcoma varies more than for many cancers, mainly with grade and subtype. About 9 in 10 conventional tumors are grade 1 or 2: they grow slowly, rarely spread, and many people are cured by surgery. For grade 1 tumors, reported 5-year survival ranges from 82% to 99%. Grade 3 tumors are more likely to spread, and dedifferentiated chondrosarcoma has a 5-year survival below 25%. Because so few people have chondrosarcoma, these figures come from small groups and are rough guides only. The tumor's location, its size and how completely it was removed also affect an individual's outlook. Life after surgery depends on what was removed and rebuilt. Surgery on the pelvis or near a major joint can affect walking and movement, and how much function returns depends on the operation and the reconstruction. Chondrosarcoma can come back where it started or spread elsewhere, sometimes years after treatment, and clear cell chondrosarcoma has recurred decades later. For that reason, follow-up visits with examinations and imaging continue for many years.
See a doctor about bone or joint pain that persists, keeps getting worse or wakes you at night, or about a new hard lump on a bone. If you have hereditary multiple osteochondromas, Ollier disease or Maffucci syndrome, also report any known cartilage growth that starts to enlarge or becomes painful. Seek same-day care for a bone that breaks with little or no injury. If you have a tumor in the pelvis or spine, contact your care team right away about new trouble controlling your bladder or bowels, or new weakness or numbness in your legs. After treatment, tell your care team about new pain, swelling or a lump near the treated area rather than waiting for the next scheduled scan.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Chondrosarcoma is like, what's helped you, or ask the community a question.